Patents by Inventor Rodney Gene Keck

Rodney Gene Keck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions including variants of vascular endothelial cell growth factor having altered pharmacological properties
    Patent number: 7208472
    Abstract: Described herein are pharmaceutical compositions including vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminal heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: April 24, 2007
    Assignee: Genentech, Inc.
    Inventors: Thomas F. Zioncheck, Geralyn G. DeGuzman, Rodney Gene Keck
  • Pharmaceutical compositions including variants of vascular endothelial cell growth factor having altered pharmacological properties
    Publication number: 20030032145
    Abstract: Described herein are pharmaceutical compositions including vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminal heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.
    Type: Application
    Filed: July 19, 2002
    Publication date: February 13, 2003
    Applicant: Genentech, Inc.
    Inventors: Thomas F. Zioncheck, Geralyn G. DeGuzman, Rodney Gene Keck
  • Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
    Patent number: 6485942
    Abstract: Described herein are vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminus heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: November 26, 2002
    Assignee: Genentech, Inc.
    Inventors: Thomas F. Zioncheck, Geralyn G. DeGuzman, Rodney Gene Keck